Venus Remedies Limited Secures Renewal of DSIR Recognition for In-house R&D Unit
Venus Remedies Limited has secured the renewal of its in-house Research & Development recognition from the Department of Scientific and Industrial Research (DSIR), Government of India. The renewal pertains to the company's dedicated R&D unit, the Venus Medicine Research Centre (VMRC).The DSIR recognition is granted to organizations that operate a specific in-house R&D unit, provided they possess defined research objectives, qualified scientific staff, and separately accounted R&D expenditure. This renewed status confirms that VMRC continues to meet these stipulated conditions for maintaining its high standard of dedicated research.
This crucial recognition supports VMRC's continuing work focused on antimicrobial resistance. Among the ongoing projects is the development of VRP-034, a novel polymyxin 8 formulation which holds the USFDA Qualified Infectious Disease Product (QIDP) designation. Furthermore, the renewed status helps sustain the GASAR resistance surveillance study being conducted by the company.
VENUSREM Stock Price Movement
Venus Remedies Limited shares rallied strongly today, settling at ₹1555.80 after closing up 4.99%. The stock finished at its 52-week high, with a trading volume of 282,923 shares recorded during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.